Portage Biotech Inc. – NASDAQ:PRTG
Portage Biotech stock price today
Portage Biotech stock price monthly change
Portage Biotech stock price quarterly change
Portage Biotech stock price yearly change
Portage Biotech key metrics
Market Cap | 6.39M |
Enterprise value | N/A |
P/E | -2.43 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.31 |
PEG ratio | -0.54 |
EPS | -6.5 |
Revenue | N/A |
EBITDA | -15.97M |
Income | -109.79M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePortage Biotech stock price history
Portage Biotech stock forecast
Portage Biotech financial statements
| Sep 2021 | 0 | -2.97M | |
|---|---|---|---|
| Dec 2021 | 0 | -3.51M | |
| Mar 2022 | 0 | -8.86M | |
| Mar 2023 | 0 | -94.44M |
| 2028 | 2.5M | -17.40M | -696.34% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-03-02 | -0.23 | -0.26 |
|---|---|---|
| 2023-07-31 | 0.26 | -5.84 |
| Jun 2022 | 192878000 | 27.86M | 14.45% |
|---|---|---|---|
| Sep 2022 | 216525000 | 38.71M | 17.88% |
| Dec 2022 | 210683000 | 42.38M | 20.12% |
| Mar 2023 | 99129000 | 23.73M | 23.94% |
| Sep 2021 | -1.27M | 0 | -81K |
|---|---|---|---|
| Dec 2021 | -1.65M | 0 | 0 |
| Mar 2022 | -2.25M | 0 | 0 |
| Mar 2023 | -4.68M | -8.94K | 2.12M |
Portage Biotech alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Portage Biotech other data
| Insider | Compensation |
|---|---|
Dr. Ian B. Walters M.B.A., M.D. (1968) Chief Executive Officer & Director | $568,500 |
Mr. Allan J. Lee Shaw CPA (1964) Chief Financial Officer | $209,950 |
-
What's the price of Portage Biotech stock today?
One share of Portage Biotech stock can currently be purchased for approximately $8.26.
-
When is Portage Biotech's next earnings date?
Unfortunately, Portage Biotech's (PRTG) next earnings date is currently unknown.
-
Does Portage Biotech pay dividends?
No, Portage Biotech does not pay dividends.
-
How much money does Portage Biotech make?
Portage Biotech has a market capitalization of 6.39M. Portage Biotech made a loss 75.34M US dollars in net income (profit) last year or -$5.84 on an earnings per share basis.
-
What is Portage Biotech's stock symbol?
Portage Biotech Inc. is traded on the NASDAQ under the ticker symbol "PRTG".
-
What is Portage Biotech's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Portage Biotech?
Shares of Portage Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Portage Biotech's key executives?
Portage Biotech's management team includes the following people:
- Dr. Ian B. Walters M.B.A., M.D. Chief Executive Officer & Director(age: 57, pay: $568,500)
- Mr. Allan J. Lee Shaw CPA Chief Financial Officer(age: 61, pay: $209,950)
-
How many employees does Portage Biotech have?
As Jul 2024, Portage Biotech employs 7 workers.
-
When Portage Biotech went public?
Portage Biotech Inc. is publicly traded company for more then 23 years since IPO on 2 Jan 2002.
-
What is Portage Biotech's official website?
The official website for Portage Biotech is portagebiotech.com.
-
How can i contact Portage Biotech?
Portage Biotech can be reached via phone at +20 3 2217378.
Portage Biotech company profile:
Portage Biotech Inc.
portagebiotech.comNASDAQ
7
Biotechnology
Healthcare
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Tortola, VG1110
CIK: 0001095435
ISIN: VGG7185A1286
CUSIP: G7185A128
